Key result
Natriuretic peptide-based therapeutics, including modified peptides and oral drugs, are being developed to optimize treatments for heart failure, hypertension, and dwarfism.
Why the study?
Optimizing natriuretic peptide therapeutics across disease states requires addressing drug metabolism, delivery systems, and target receptors.
This review summarizes the physiological effects, drug metabolism, delivery systems, and therapeutic potential of natriuretic peptides and their receptors in disease states such as heart failure and hypertension.
No takes yet. Share an insight, caveat, or question.
Ongoing natriuretic peptide therapeutic development merits awareness; leaves open clinical adoption pending randomized efficacy data.
Ichiki et al. (2022) conducted a review in Heart failure, hypertension, and dwarfism. Natriuretic peptide-based therapeutics was evaluated. Natriuretic peptide-based therapeutics, including modified peptides and oral drugs, are being developed to optimize treatments for heart failure, hypertension, and dwarfism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: